Becton Dickinson & Co (BDX) Stock Analysis and Metrics

Becton Dickinson

NYSE: BDX

$156.37 ▲ +3.40 (+2.22%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap43.92 Bn

P/E37.38

P/S2.06

Div. Yield0.03

ROIC (Qtr)0.00

Total Debt (Qtr)17.28 Bn

Revenue Growth (1y) (Qtr)5.22

Add ratio to table…

About

Becton Dickinson and Company is a global medical technology company engaged in the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. The company serves healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. BD provides customer solutions focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology care, enhancing the diagnosis of infectious diseases and cancers, and advancing cellular research and applications.

BD generates revenue through the sale of its medical technologies and devices across multiple product lines. The company earns income from medication delivery solutions such as peripheral intravenous catheters, central lines, vascular access technology, and needle-free IV connectors. Revenue is also derived from medication management solutions including infusion pumps, automated medication dispensing systems, and pharmacy automation systems. Additional revenue streams come from pharmaceutical systems like prefillable drug delivery systems, advanced patient monitoring systems, diagnostic solutions for infectious diseases and cancers, biosciences research tools, specimen management products, and interventional specialty products for vascular, urology, oncology, and surgical applications.

The company operates through the following segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences.

• Medical Essentials produces a broad array of medical technologies and devices used to improve healthcare delivery in various settings, including peripheral intravenous catheters, advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care products, vascular preparation items, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detection systems, conventional and safety hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems.

• Connected Care includes IV medication safety and infusion therapy delivery systems such as infusion pumps, dedicated disposables, and IV fluids; medication compounding workflow systems; automated medication dispensing; automated supply management systems; medication inventory optimization and tracking systems; informatics and analytics solutions for enterprise medication management; and pharmacy automation systems.

• BioPharma Systems provides prefillable drug delivery systems—prefillable syringes, safety, shielding, and self-injection systems and support services—to pharmaceutical companies for use as containers for injectable pharmaceutical products, which are then placed on the market as drug/device combinations.

• Interventional provides vascular, urology, oncology, and surgical specialty products intended for single use or temporary or permanent implantation, including hernia and soft tissue repair products, biological and bioresorbable grafts, biosurgery products, BD Surgiphor™ Antimicrobial Irrigation System, BD ChloraPrep™ surgical infection prevention products, percutaneous transluminal angioplasty balloon catheters, radio frequency ablation catheters, peripheral vascular stents, self-expanding and balloon-expandable stent grafts, vascular grafts, drug coated balloons, ports, biopsy devices, chronic dialysis equipment, inferior vena cava filters, endovascular fistula creation devices, drainage products, atherectomy and thrombectomy systems, urine management and measurement devices, indwelling, intermittent and external urine catheters, kidney stone management devices, targeted temperature management systems, and fecal management devices.

• Life Sciences provides products for the safe collection and transport of diagnostic specimens, instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers, and research and clinical tools that facilitate the study of cells and cellular components to aid in drug and vaccine development and disease diagnosis and management, including automated blood culturing and tuberculosis culturing systems, microorganism identification and drug susceptibility systems, microbiology laboratory automation and informatics, dehydrated, liquid, and plated media for clinical and industrial microbiology applications, molecular testing systems for infectious diseases and women’s health, rapid diagnostic assays for point-of-care respiratory infection testing, fluorescence-activated cell sorters and analyzers, antibodies and kits for cell analysis, reagents for life science research, solutions for high-throughput single-cell gene and protein expression analysis, and clinical oncology, immunological (HIV), and transplantation diagnostic/monitoring reagents, analyzers, and informatics.

BD operates in the increasingly complex and challenging medical technology marketplace, competing with companies of varying sizes that have greater financial resources or specialization in niche markets such as molecular diagnostics, non-traditional point of care, at-home testing, safety-engineered devices, and life sciences. The company maintains its competitive position through investments in research and development, quality management, product innovation, manufacturing, and supply chain improvements, leveraging factors such as price, quality, innovation, service, reputation, distribution, and promotion to differentiate its offerings.

BD serves hospitals and clinics, physician office practices, consumers and retail pharmacies, governmental and nonprofit public health agencies, pharmaceutical companies, healthcare workers, hospitals, laboratories and clinics, blood banks, academic and government institutions, pharmaceutical and biotechnology companies, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business.

Investment Thesis

▲ Bull case

Becton, Dickinson and Company is positioned for sustained margin expansion and earnings acceleration through the deepening integration of BD Excellence across commercial and R&D functions, which is generating productivity gains that are both persistent and scalable. The company delivered 8% productivity in Q2 FY26, with management noting this level of improvement is consistent with prior quarters and driven by disciplined Kaizen events now exceeding 2,000 annually across the organization. This operational framework is not only reducing costs but also improving service levels above 90%, enabling faster order fulfillment and stronger customer retention. Crucially, BD Excellence is being extended beyond manufacturing into sales execution and R&D, where it has already reduced time-to-launch by over 10 months on average for five development programs. This acceleration in innovation cycles allows BD to capitalize faster on high-growth markets like GLP-1 drug delivery and Advanced Patient Monitoring, creating a self-reinforcing flywheel where commercial success funds further R&D investment. The market is underestimating how this systemic operational advantage will compound over time, particularly as the company continues to rationalize its global footprint to approximately 50 sites — down from over 100 just a few years ago — enabling greater scale, automation, and AI integration in facilities that support high-margin platforms.
Becton, Dickinson and Company’s capital allocation strategy is creating a powerful tailwind for shareholder returns that is not fully reflected in current valuations, as the company prioritizes share repurchases at what management views as a substantially undervalued stock price. During Q2 FY26, BD returned $2.3 billion to shareholders, including $2.0 billion in repurchases and $0.3 billion in dividends, while simultaneously retiring $2.1 billion in debt, reducing net leverage to 2.9x from over 3.5x at the start of the year. Management explicitly stated they believe the current stock price represents a compelling opportunity for value creation through buybacks, citing disciplined execution and strong cash flow generation as enablers. With year-to-date free cash flow of $1.1 billion — significantly higher than the prior period due to improved working capital and inventory efficiency — and a long-term leverage target of 2.5x, BD has ample capacity to sustain aggressive repurchases even while funding tuck-in M&A in high-growth areas. The market is overlooking how this dual focus on debt reduction and shareholder return, coupled with a clear framework that ranks buybacks above M&A at current valuations, will consistently boost EPS through share count reduction independent of operational performance.
Becton, Dickinson and Company’s Biologics platform within BioPharma Systems is becoming an increasingly dominant and high-margin contributor to long-term growth, with management confirming it now represents approximately 55% of segment revenue — up from 50% just prior to the earnings call — despite the segment’s overall decline of 1.8% due to vaccine weakness. This shift is being driven by two significant long-term GLP-1 customer wins with leading global pharmaceutical companies and over 80 biosimilar deals signed, which offer higher average selling prices than novel GLP-1s due to device differentiation in pens and auto-injectors. Unlike the volatile vaccine business, Biologics growth is rooted in secular trends around obesity and diabetes treatment, with injectable GLP-1 expected to remain the backbone of the market even as oral alternatives emerge, which management views as incremental and complementary. The company is strategically increasing sales force coverage and R&D investment in this area, including support for next-generation molecules and tissue-protective formulations. The market is failing to appreciate how the rising weight of this high-growth, high-margin platform will steadily lift the overall profitability and growth profile of BioPharma Systems, turning a segment currently seen as a drag into a durable engine of value creation as vaccine headwinds fade.

Becton, Dickinson and Company is positioned for sustained margin expansion and earnings acceleration through the deepening integration of BD Excellence across commercial and R&D functions, which is generating productivity gains that are both persistent and scalable. The company delivered 8% productivity in Q2 FY26, with management noting this level of improvement is consistent with prior quarters and driven by disciplined Kaizen events now exceeding 2,000 annually across the organization. This operational framework is not only reducing costs but also improving service levels above 90%, enabling faster order fulfillment and stronger customer retention. Crucially, BD Excellence is being extended beyond manufacturing into sales execution and R&D, where it has already reduced time-to-launch by over 10 months on average for five development programs. This acceleration in innovation cycles allows BD to capitalize faster on high-growth markets like GLP-1 drug delivery and Advanced Patient Monitoring, creating a self-reinforcing flywheel where commercial success funds further R&D investment. The market is underestimating how this systemic operational advantage will compound over time, particularly as the company continues to rationalize its global footprint to approximately 50 sites — down from over 100 just a few years ago — enabling greater scale, automation, and AI integration in facilities that support high-margin platforms.
Becton, Dickinson and Company’s capital allocation strategy is creating a powerful tailwind for shareholder returns that is not fully reflected in current valuations, as the company prioritizes share repurchases at what management views as a substantially undervalued stock price. During Q2 FY26, BD returned $2.3 billion to shareholders, including $2.0 billion in repurchases and $0.3 billion in dividends, while simultaneously retiring $2.1 billion in debt, reducing net leverage to 2.9x from over 3.5x at the start of the year. Management explicitly stated they believe the current stock price represents a compelling opportunity for value creation through buybacks, citing disciplined execution and strong cash flow generation as enablers. With year-to-date free cash flow of $1.1 billion — significantly higher than the prior period due to improved working capital and inventory efficiency — and a long-term leverage target of 2.5x, BD has ample capacity to sustain aggressive repurchases even while funding tuck-in M&A in high-growth areas. The market is overlooking how this dual focus on debt reduction and shareholder return, coupled with a clear framework that ranks buybacks above M&A at current valuations, will consistently boost EPS through share count reduction independent of operational performance.
Becton, Dickinson and Company’s Biologics platform within BioPharma Systems is becoming an increasingly dominant and high-margin contributor to long-term growth, with management confirming it now represents approximately 55% of segment revenue — up from 50% just prior to the earnings call — despite the segment’s overall decline of 1.8% due to vaccine weakness. This shift is being driven by two significant long-term GLP-1 customer wins with leading global pharmaceutical companies and over 80 biosimilar deals signed, which offer higher average selling prices than novel GLP-1s due to device differentiation in pens and auto-injectors. Unlike the volatile vaccine business, Biologics growth is rooted in secular trends around obesity and diabetes treatment, with injectable GLP-1 expected to remain the backbone of the market even as oral alternatives emerge, which management views as incremental and complementary. The company is strategically increasing sales force coverage and R&D investment in this area, including support for next-generation molecules and tissue-protective formulations. The market is failing to appreciate how the rising weight of this high-growth, high-margin platform will steadily lift the overall profitability and growth profile of BioPharma Systems, turning a segment currently seen as a drag into a durable engine of value creation as vaccine headwinds fade.

▼ Bear case

Becton, Dickinson and Company faces persistent and structurally challenging headwinds in its Alaris infusion systems business that are being underestimated by management, with a 200 basis point revenue drag anticipated for FY27 — double the current year’s impact — due to lapping against a strong post-remediation upgrade cycle. While management highlighted 150 basis points of year-to-date share gains and zero infusion account losses in Q2, they acknowledged the business is still cycling against elevated demand from the 2023–2024 Alaris replacement wave, which created an artificially high base for year-over-year comparisons. The CFO explicitly noted that the 200 basis point FY27 headwind stems from this higher ‘26 base, not ongoing weakness, implying that once the comparison normalizes in FY28, underlying Alaris performance may still be flat or modestly negative absent new innovation. Despite share gains, the company conceded that MMS (which includes Alaris) grew only 3.3% FX-neutral, with pump capital performance modest and disposable sets benefiting from an easy prior-year comparison tied to fluid supply disruptions. The market is ignoring that Alaris, while gaining share, operates in a mature, intensely competitive segment where unit growth is limited by hospital budget cycles and long replacement tails, making sustained mid-single-digit growth unlikely without disruptive innovation — which has not yet materialized in the pipeline.
Becton, Dickinson and Company’s gross margin resilience is fragile and overly dependent on temporary offsetting factors, with tariffs continuing to exert a significant 160 basis point drag that is only partially mitigated by productivity gains and mix shifts, leaving the company vulnerable to any deterioration in its cost offset mechanisms. Adjusted gross margin declined 90 basis points year-over-year to 54.7%, despite 70 basis points of positive benefit from productivity and mix, meaning the underlying business would have contracted by 160 basis points without these offsets. Management cited hedging programs for North American resins (covering ~50% of usage) and diversified sourcing as protections against oil and resin volatility, but acknowledged these are time-bound solutions, with the CFO noting teams are already working to offset costs through pricing and efficiencies heading into FY27. The company’s reliance on pricing actions to combat raw material inflation is particularly risky in a value-based procurement environment, especially in international markets like China, where BD represents only 4% of revenue and is explicitly stated to be losing share to lower-cost competitors. If productivity gains from BD Excellence plateau or tariff relief fails to materialize, gross margin could quickly revert to a downward trend, undermining the credibility of the 25% full-year operating margin guidance.
Becton, Dickinson and Company’s Interventional segment, while showing 5.3% FX-neutral growth in Q2, is exposed to significant execution risk due to leadership turnover and integration challenges following the recent appointment of Peter Menziuso from Johnson & Johnson Vision as president of the division. Although Menziuso brings strong credentials in leading a $5 billion global business, his background is in vision care — a sector with fundamentally different dynamics, reimbursement models, and sales cycles than the complex, procedure-driven interventional markets BD serves, including peripheral intervention, urology, and surgery. The market is overlooking that transitioning leadership from a high-volume, consumer-facing diagnostic device business to a clinical, physician-preference-driven interventional franchise may result in misaligned go-to-market strategies, particularly in areas like vascular covered stents and advanced tissue regeneration where physician education and hospital committee approvals are critical. While Menziuso’s operational excellence background is a plus, the lack of direct interventional experience raises concerns about his ability to navigate nuanced stakeholder relationships and technical adoption barriers, potentially slowing the commercial uptake of recent launches like the Revello Vascular Covered Stent and Elyra™ Thulium Fiber Laser System, which are critical to sustaining the segment’s growth trajectory amid rising competition from specialized pure-players.

Becton, Dickinson and Company faces persistent and structurally challenging headwinds in its Alaris infusion systems business that are being underestimated by management, with a 200 basis point revenue drag anticipated for FY27 — double the current year’s impact — due to lapping against a strong post-remediation upgrade cycle. While management highlighted 150 basis points of year-to-date share gains and zero infusion account losses in Q2, they acknowledged the business is still cycling against elevated demand from the 2023–2024 Alaris replacement wave, which created an artificially high base for year-over-year comparisons. The CFO explicitly noted that the 200 basis point FY27 headwind stems from this higher ‘26 base, not ongoing weakness, implying that once the comparison normalizes in FY28, underlying Alaris performance may still be flat or modestly negative absent new innovation. Despite share gains, the company conceded that MMS (which includes Alaris) grew only 3.3% FX-neutral, with pump capital performance modest and disposable sets benefiting from an easy prior-year comparison tied to fluid supply disruptions. The market is ignoring that Alaris, while gaining share, operates in a mature, intensely competitive segment where unit growth is limited by hospital budget cycles and long replacement tails, making sustained mid-single-digit growth unlikely without disruptive innovation — which has not yet materialized in the pipeline.
Becton, Dickinson and Company’s gross margin resilience is fragile and overly dependent on temporary offsetting factors, with tariffs continuing to exert a significant 160 basis point drag that is only partially mitigated by productivity gains and mix shifts, leaving the company vulnerable to any deterioration in its cost offset mechanisms. Adjusted gross margin declined 90 basis points year-over-year to 54.7%, despite 70 basis points of positive benefit from productivity and mix, meaning the underlying business would have contracted by 160 basis points without these offsets. Management cited hedging programs for North American resins (covering ~50% of usage) and diversified sourcing as protections against oil and resin volatility, but acknowledged these are time-bound solutions, with the CFO noting teams are already working to offset costs through pricing and efficiencies heading into FY27. The company’s reliance on pricing actions to combat raw material inflation is particularly risky in a value-based procurement environment, especially in international markets like China, where BD represents only 4% of revenue and is explicitly stated to be losing share to lower-cost competitors. If productivity gains from BD Excellence plateau or tariff relief fails to materialize, gross margin could quickly revert to a downward trend, undermining the credibility of the 25% full-year operating margin guidance.
Becton, Dickinson and Company’s Interventional segment, while showing 5.3% FX-neutral growth in Q2, is exposed to significant execution risk due to leadership turnover and integration challenges following the recent appointment of Peter Menziuso from Johnson & Johnson Vision as president of the division. Although Menziuso brings strong credentials in leading a $5 billion global business, his background is in vision care — a sector with fundamentally different dynamics, reimbursement models, and sales cycles than the complex, procedure-driven interventional markets BD serves, including peripheral intervention, urology, and surgery. The market is overlooking that transitioning leadership from a high-volume, consumer-facing diagnostic device business to a clinical, physician-preference-driven interventional franchise may result in misaligned go-to-market strategies, particularly in areas like vascular covered stents and advanced tissue regeneration where physician education and hospital committee approvals are critical. While Menziuso’s operational excellence background is a plus, the lack of direct interventional experience raises concerns about his ability to navigate nuanced stakeholder relationships and technical adoption barriers, potentially slowing the commercial uptake of recent launches like the Revello Vascular Covered Stent and Elyra™ Thulium Fiber Laser System, which are critical to sustaining the segment’s growth trajectory amid rising competition from specialized pure-players.

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password